NCT01292993

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

A Phase 1, Randomized, Open-Label, 3-Period, 3-Treatment, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of LX4211 and Metformin in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the effects of LX4211 and metformin on each other when given at the same time as single doses to healthy human subjects.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	400 mg LX4211	400 mg of LX4211 given as a solid oral dose form
DRUG	1000 mg metformin	1000 mg metformin given as a solid oral dose form

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-03-01
• First posted: 2011-02-10
• Last updated: 2011-03-30

Locations

1 site across 1 country: United States